Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce
Li Tang, Diego R. Hijano, Aditya H. Gaur, Terrence L. Geiger, Ellis J. Neufeld, James M. Hoffman, Randall T. Hayden
Abstract
This study aims to describe an association between the Pfizer-BioNTech (BNT162b2) vaccine and decreased risk of symptomatic and asymptomatic infections with SARS-CoV-2 in hospital employees.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)AsymptomaticCoronavirus disease 2019 (COVID-19)Vaccination2019-20 coronavirus outbreakWorkforceVirologyPandemicTiterOutbreakInternal medicineVirusDiseaseInfectious disease (medical specialty)EconomicsEconomic growthSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies